News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • Dr. Lawrence Shulman led the effort in determining which cancer drugs should be included in the World Health Organization's List of Essential Medicines.

Tags: Disparities

  • New research suggests that cholesterol-lowering statin drugs could be a valuable addition to current therapies for prostate cancer.

Tags: ProstateCancer

  • After identifying three different types of resistance to a promising investigational lung cancer drug, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors’ constant and varied molecular shape-shifting.

Tags: LungCancer

  • A study led by Pasi Jänne, MD, PhD, found that an experimental drug targeted to the resistance mutation is highly active in patients with EGFR-positive non-small cell lung cancer (NSCLC) when the disease progressed during treatment with front-line inhibitor drugs.

Tags: LungCancer, Genetics

  • Bruce Spiegelman, PhD, Dana-Farber Cancer Institute, has received Belgium's most important international scientific prize for his contributions to understanding the mechanisms of metabolic disorders.

Tags: BasicResearch, Honors

  • In a new study, researchers at Dana-Farber Cancer Institute show that disruptions to the activity of cell proteins can reveal which genetic mutations lead to disease and which are mere bystanders.

Tags: BasicResearch

  • Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health in Boston and the Irish Cancer Society have formed the Boston-Ireland Prostate Cancer Collaboration. This new entity will conduct and facilitate exchanges of researchers and knowledge between Boston and Ireland.

Tags: BasicResearch, ProstateCancer

  • Dana-Farber researchers report that combination treatment with olaparib and BKM120 was safe and yielded evidence of clinical benefit for women with triple-negative breast cancer and for those with high-grade serous ovarian cancer in a phase I clinical trial.

Tags: OvarianCancer, TranslationalResearch

  • Dana-Farber researchers report in the New England Journal of Medicine that treating advanced melanoma patients initially with the combination of the immunotherapy drugs nivolumab and ipilimumab achieves a much higher response rate than treatment with ipilimumab alone.

Tags: Melanoma, Immunotherapy

  • Dana-Farber's Alan D'Andrea, MD, has been selected to lead a Stand Up To Cancer Dream Team devoted to ovarian cancer research. The team will focus on DNA repair therapies for ovarian cancer.

Tags: OvarianCancer, TranslationalResearch

Showing 11-20 of 598 items